Prevymis™ (letermovir) – New orphan drug approval
November 9, 2017 – Merck announced the FDA approval of Prevymis (letermovir), for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Download PDF
